Combined heart and lung transplantation.

Area of Science:

• Cardiovascular Surgery
• Pulmonary Medicine
• Transplantation Immunology

Background:

• Pulmonary hypertension, including primary forms and Eisenmenger's syndrome, represents a severe, often fatal, condition.
• Limited therapeutic options exist for patients with advanced pulmonary hypertension and Eisenmenger's syndrome.
• Combined heart-lung transplantation has emerged as a potential treatment modality.

Purpose of the Study:

• To evaluate the efficacy and outcomes of combined heart-lung transplantation in patients with severe pulmonary hypertension.
• To assess the survival rates and functional recovery following this procedure.
• To identify and analyze late complications and their potential management.

Main Methods:

• Retrospective analysis of 27 combined heart-lung transplantation cases at Stanford University Medical Center.
• Focus on patient populations with primary pulmonary hypertension and Eisenmenger's syndrome.
• Evaluation of one-year survival, functional status, and incidence of late complications.

Main Results:

• A one-year survival rate of approximately 70% was achieved in the studied cohort.
• All surviving recipients returned to normal activity levels post-transplantation.
• Late respiratory difficulties occurred in some patients, necessitating retransplantation in one case, likely due to rejection.

Conclusions:

• Combined heart-lung transplantation is an effective therapy for otherwise fatal pulmonary conditions, including Eisenmenger's syndrome.
• This procedure offers a novel therapeutic avenue for Eisenmenger's syndrome.
• Further experience and improved rejection management may mitigate late complications and enhance long-term outcomes.